UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported) September 30, 2011 (September 28, 2011)
Cephalon, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
0-19119 |
|
23-2484489 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of Incorporation) |
|
File Number) |
|
Identification No.) |
|
41 Moores Road |
|
|
|
Frazer, Pennsylvania |
|
19355 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (610) 344-0200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On September 28, 2011, we received a subpoena duces tecum from the U.S. Department of Justice requesting documents regarding certain promotional practices relating to the Company’s products, NUVIGIL® (armodafinil) and PROVIGIL® (modafinil). The Company is in the process of responding to the subpoena and intends to cooperate fully.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CEPHALON, INC. | |
|
|
| |
|
|
| |
|
Date: September 30, 2011 |
By: |
/s/ Gerald J. Pappert |
|
|
|
Gerald J. Pappert |
|
|
|
Executive Vice President and General Counsel |